Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies
about
Use of licensed vaccines for active immunization of the immunocompromised hostHost immunity to Cryptococcus neoformansImproved survival of mice deficient in secretory immunoglobulin M following systemic infection with Cryptococcus neoformansIgM(+) memory B cell expression predicts HIV-associated cryptococcosis status.Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in miceThe capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibodyContribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal diseaseEfficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice.An opsonizing monoclonal antibody that recognizes a noncapsular epitope expressed on Cryptococcus neoformans.Antifungal activity of a human antiglucuronoxylomannan antibody.Prospects for the development of fungal vaccines.A role for B cells in resistance to Cryptococcus neoformans in mice.
P2860
Q24533456-DC04DFFF-2160-490B-84AE-7231B6C0D262Q26823438-E9BD6C7F-8CF0-4EEE-A289-B927F50F8B82Q33557968-2828E8AF-D81B-48DE-8F6F-F28E7700F55DQ33585837-34A7AE54-71FD-4E96-BDFF-4BCBDCE9A09EQ33751509-F67B8326-6766-49DB-A105-D70950AC67E3Q34001769-F5C2D0F4-8DD9-470C-AC50-B802BE69C934Q34779166-1E17915A-2D51-42A2-9883-B41DE13CC483Q35544888-03F57FE0-AFD7-474F-B40C-D854BF764D80Q35783722-9A6228FD-E258-4CAF-AD31-DCD448F59175Q36228216-0A02FDAA-4ABA-415C-B50A-A264D1DA756CQ37140093-45697849-4D22-454B-BC17-A78302B7B0BBQ37145037-709EAC71-588A-45CF-AD25-C251C95771EEQ39512151-CB8F473C-0734-4F4C-A868-8A5D127D3925Q39630861-B7779DB4-EF1E-411D-B3C4-3301CD3504D5Q39820834-8C134144-6958-4A9E-BCD1-36E34F46145EQ39833183-BEF4A4F4-253F-40EE-932D-AA94A935BCA5
P2860
Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies
description
1996 nî lūn-bûn
@nan
1996 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Opsonization of Cryptococcus n ...... glucuronoxylomannan antibodies
@ast
Opsonization of Cryptococcus n ...... glucuronoxylomannan antibodies
@en
type
label
Opsonization of Cryptococcus n ...... glucuronoxylomannan antibodies
@ast
Opsonization of Cryptococcus n ...... glucuronoxylomannan antibodies
@en
prefLabel
Opsonization of Cryptococcus n ...... glucuronoxylomannan antibodies
@ast
Opsonization of Cryptococcus n ...... glucuronoxylomannan antibodies
@en
P2860
P1476
Opsonization of Cryptococcus n ...... glucuronoxylomannan antibodies
@en
P2093
P2860
P304
P407
P577
1996-09-01T00:00:00Z